Prognostic factors in patients with metastatic malignant melanoma: A multivariate analysis

Background. Current methods to predict survival in patients with advanced, metastatic melanoma are limited. To determine clinical prognostic factors that accurately predict survival in patients with metastatic melanoma, a retrospective analysis was performed.

[1]  C. Cordon-Cardo,et al.  Treatment with high dose mouse monoclonal (anti‐GD3) antibody R24 in patients with metastatic melanoma , 1992, Melanoma research.

[2]  C. Dunton,et al.  Poor prognosis associated with thrombocytosis in patients with cervical cancer , 1992, Cancer.

[3]  A. Kopf,et al.  Influence of gender on survival in patients with stage I malignant melanoma. , 1992, Journal of the American Academy of Dermatology.

[4]  D. Bajorin,et al.  A phase II trial of high‐dose cisplatin and dacarbazine. Lack of efficacy of high‐dose, cisplatin‐based therapy for metastatic melanoma , 1991, Cancer.

[5]  J. Crowley,et al.  Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Tong,et al.  Cancer statistics, 1991 , 1991, CA: a cancer journal for clinicians.

[7]  D. Payne,et al.  The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Sober,et al.  Prognosis after initial recurrence of cutaneous melanoma. , 1991, Archives of surgery.

[9]  R. Holle,et al.  Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. , 1991, British Journal of Cancer.

[10]  E. Noordijk,et al.  Erythrocyte Sedimentation Rate Predicts Early Relapse and Survival in Early-Stage Hodgkin Disease , 1991 .

[11]  A. Levis,et al.  Prognostic significance of serum albumin in chronic lymphocytic leukemia. , 1991, Haematologica.

[12]  M. Urist,et al.  Histopathological prognostic factors of certain primary oral cavity cancers. , 1990, Oncology.

[13]  C. Cordon-Cardo,et al.  Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. , 1990, Cancer research.

[14]  K. Heimdal,et al.  Regression analyses of prognostic factors in metastatic malignant melanoma. , 1989, European journal of cancer & clinical oncology.

[15]  Livingston Po.  Experimental and clinical studies with active specific immunotherapy. , 1989 .

[16]  P. Livingston.  Experimental and clinical studies with active specific immunotherapy. , 1989, Progress in clinical and biological research.

[17]  D. Trump,et al.  Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. , 1988, Cancer research.

[18]  C. McClain,et al.  Tumor necrosis factor-mediated hypoalbuminemia in rabbits. , 1988, The Journal of nutrition.

[19]  C. Slingluff,et al.  Stage II malignant melanoma: Presentation of a prognostic model and an assessment of specific active immunotherapy in 1,273 patients , 1988, Journal of surgical oncology.

[20]  S. Tsugane,et al.  Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Pawlicki,et al.  Prognostic Factors in Advanced Metastatic and Recurrent Melanoma Treated with DTIC , 1987, Tumori.

[22]  S. Groshen,et al.  Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  H. Colten,et al.  Regulation of class III major histocompatibility complex gene products by interleukin-1. , 1986, Science.

[24]  R. Bataille,et al.  Prognostic factors and staging in multiple myeloma: a reappraisal. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. S. Khan,et al.  Prognostic factors in malignant melanoma: a retrospective analysis of 182 patients. , 1985, Clinical radiology.

[26]  S. Jagannath,et al.  Stage IV diffuse large-cell lymphoma: a long-term analysis. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  P. Vezzoni,et al.  Lactate Dehydrogenase Levels in Cellular Extracts of Human Malignant Lymphomas , 1983, Tumori.

[28]  N. Geller,et al.  Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. , 1983, Cancer research.

[29]  A. Giuliano,et al.  LDH and melanoma , 1983, Cancer.

[30]  C. Balch,et al.  A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  C. Balch,et al.  A Comparison of Prognostic Factors and Surgical Results in 1,786 Patients with Localized (Stage I) Melanoma Treated in Alabama, USA, and New South Wales, Australia , 1982, Annals of surgery.

[32]  R. Benjamin,et al.  The natural history of resectable metastatic melanoma (Stage IVA Melanoma) , 1982, Cancer.

[33]  E. Gehan,et al.  A prognostic factor analysis for use in development of predictive models for response in adult acute leukemia , 1982, Cancer.

[34]  A. Bartolucci,et al.  Prognostic factors in metastatic malignant melanoma. The southeastern cancer study group experience , 1982, Cancer.

[35]  J. Crowley,et al.  Prognostic value of serum lactic dehydrogenase level in Hodgkin's disease. , 1982, The Journal of laboratory and clinical medicine.

[36]  C. Balch,et al.  A Multifactorial Analysis of Melanoma: III. Prognostic Factors in Melanoma Patients with Lymph Node Metastases (Stage II) , 1981, Annals of surgery.

[37]  C. Balch,et al.  The prognostic significance of ulceration of cutaneous melanoma , 1980, Cancer.

[38]  V. Vaitkevicius,et al.  Clinical presentation, natural history and prognostic factors in advanced malignant melanoma. , 1979, Surgery, gynecology & obstetrics.

[39]  W. Berry,et al.  Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate , 1979, Cancer.

[40]  C. Balch,et al.  A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma. , 1979, Surgery.

[41]  C. Balch,et al.  A Multifactorial Analysis of Melanoma: Prognostic Histopathological Features Comparing Clark's and Breslow's Staging Methods , 1978, Annals of surgery.

[42]  D. Carr.  The manual for the staging of cancer. , 1977, Annals of internal medicine.

[43]  T. Waldmann,et al.  Pathophysiology of hypoalbuminemia associated with carcinoid tumor , 1976, Cancer.

[44]  R. Simon,et al.  Pretreatment serum lactate dehydrogenase predicting metastatic spread in Ewing's sarcoma. , 1975, Annals of internal medicine.

[45]  L. Einhorn,et al.  Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. , 1974, Cancer research.

[46]  A Breslow,et al.  Thickness, Cross‐Sectional Areas and Depth of Invasion in the Prognosis of Cutaneous Melanoma , 1970, Annals of surgery.

[47]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[48]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .